Next Article in Journal
Polyamidoamine Dendrimers Decorated Multifunctional Polydopamine Nanoparticles for Targeted Chemo- and Photothermal Therapy of Liver Cancer Model
Previous Article in Journal
Field Cancerization in NSCLC: A New Perspective on MicroRNAs in Macrophage Polarization
Previous Article in Special Issue
Combinatorial Drug Treatments Reveal Promising Anticytomegaloviral Profiles for Clinically Relevant Pharmaceutical Kinase Inhibitors (PKIs)
Open AccessReview

Novel Tyrosine Kinase Targets in Urothelial Carcinoma

Medical Oncology Department, University Hospital Ramon y Cajal, 28034 Madrid, Spain
Medical Oncology Department, Ramón y Cajal Health Research Institute (IRYCIS), CIBERONC, Alcalá University, University Hospital Ramon y Cajal, 28034 Madrid, Spain
Medical Oncology Department, Infanta Cristina Hospital, 28607 Madrid, Spain
Department of Medical Oncology, MD Anderson Cancer Center, 28033 Madrid, Spain
Authors to whom correspondence should be addressed.
These authors have contributed equally to this work.
Int. J. Mol. Sci. 2021, 22(2), 747;
Received: 20 December 2020 / Revised: 9 January 2021 / Accepted: 11 January 2021 / Published: 13 January 2021
(This article belongs to the Special Issue Advances in Kinase Drug Discovery)
Urothelial carcinoma represents one of the most prevalent types of cancer worldwide, and its incidence is expected to grow. Although the treatment of the advanced disease was based on chemotherapy for decades, the developments of different therapies, such as immune checkpoint inhibitors, antibody drug conjugates and tyrosine kinase inhibitors, are revolutionizing the therapeutic landscape of this tumor. This development coincides with the increasing knowledge of the pathogenesis and genetic alterations in urothelial carcinoma, from the non-muscle invasive setting to the metastatic one. The purpose of this article is to provide a comprehensive review of the different tyrosine kinase targets and their roles in the therapeutic scene of urothelial carcinoma. View Full-Text
Keywords: tyrosine kinase; tyrosine kinase inhibitors; urothelial carcinoma tyrosine kinase; tyrosine kinase inhibitors; urothelial carcinoma
Show Figures

Figure 1

MDPI and ACS Style

Torres-Jiménez, J.; Albarrán-Fernández, V.; Pozas, J.; Román-Gil, M.S.; Esteban-Villarrubia, J.; Carrato, A.; Rosero, A.; Grande, E.; Alonso-Gordoa, T.; Molina-Cerrillo, J. Novel Tyrosine Kinase Targets in Urothelial Carcinoma. Int. J. Mol. Sci. 2021, 22, 747.

AMA Style

Torres-Jiménez J, Albarrán-Fernández V, Pozas J, Román-Gil MS, Esteban-Villarrubia J, Carrato A, Rosero A, Grande E, Alonso-Gordoa T, Molina-Cerrillo J. Novel Tyrosine Kinase Targets in Urothelial Carcinoma. International Journal of Molecular Sciences. 2021; 22(2):747.

Chicago/Turabian Style

Torres-Jiménez, Javier; Albarrán-Fernández, Víctor; Pozas, Javier; Román-Gil, María S.; Esteban-Villarrubia, Jorge; Carrato, Alfredo; Rosero, Adriana; Grande, Enrique; Alonso-Gordoa, Teresa; Molina-Cerrillo, Javier. 2021. "Novel Tyrosine Kinase Targets in Urothelial Carcinoma" Int. J. Mol. Sci. 22, no. 2: 747.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop